

# Endolymphatic Sac Tumor Showing Increased Activity on $^{68}\text{Ga}$ DOTATATE PET/CT

Georgios Z. Papadakis, MD,\* Corina Millo, MD,† Samira M. Sadowski, MD,‡§  
Ulas Bagci, PhD,|| and Nicholas J. Patronas, MD\*

**Abstract:** Endolymphatic sac tumors (ELSTs) are rare tumors arising from the epithelium of the endolymphatic sac and duct that can be either sporadic or associated with von Hippel-Lindau (VHL) disease. We report a case of a VHL patient with histologically proven residual ELST who underwent  $^{68}\text{Ga}$  DOTATATE PET/CT showing increased activity ( $\text{SUV}_{\text{max}}$ , 6.29) by the ELST. The presented case of a VHL-associated ELST with increased  $^{68}\text{Ga}$  DOTATATE uptake indicates cell-surface expression of somatostatin receptors by this tumor, suggesting the potential application of somatostatin receptor imaging using  $^{68}\text{Ga}$  DOTA-conjugated peptides in the workup and management of these patients.

**Key Words:** endolymphatic sac tumors, von Hippel-Lindau disease,  $^{68}\text{Ga}$ -DOTATATE PET/CT, somatostatin receptors-imaging

(*Clin Nucl Med* 2016;41: 783–784)

Received for publication February 9, 2016; revision accepted May 30, 2016. From the \*Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, †Division of Nuclear Medicine, RAD&IS, Clinical Center, and ‡Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; §Endocrine and Thoracic Surgery, University Hospitals of Geneva, Geneva, Switzerland; and ||Center for Research in Computer Vision, Electrical and Computer Science Department, University of Central Florida, Orlando, FL.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Nicholas J. Patronas, MD, Section of Neuroradiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bldg 10, Room 1C361X 10, Center Dr, Bethesda MD 20814 (Mail stop 1182). E-mail: NPatronas@cc.nih.gov.


Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0363-9762/16/4110-0783

DOI: 10.1097/RLU.0000000000001315

## REFERENCES

1. Wick CC, Manzoor NF, Semaan MT, et al. Endolymphatic sac tumors. *Otolaryngol Clin North Am*. 2015;48:317–330.
2. Lonser RR, Kim HJ, Butman JA, et al. Tumors of the endolymphatic sac in von Hippel-Lindau disease. *N Engl J Med*. 2004;350:2481–2486.
3. Bambakidis NC, Rodrigue T, Megerian CA, et al. Endolymphatic sac tumor metastatic to the spine. Case report. *J Neurosurg Spine*. 2005;3:68–70.
4. Tay KY, Yu E, Kassel E. Spinal metastasis from endolymphatic sac tumor. *AJNR Am J Neuroradiol*. 2007;28:613–614.
5. Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. *Lancet*. 2003;361:2059–2067.
6. Bambakidis NC, Megerian CA, Ratcheson RA. Differential grading of endolymphatic sac tumor extension by virtue of von Hippel-Lindau disease status. *Otol Neurotol*. 2004;25:773–781.
7. Gläsker S, Lonser RR, Tran MG, et al. Effects of VHL deficiency on endolymphatic duct and sac. *Cancer Res*. 2005;65:10847–10853.
8. Leung RS, Biswas SV, Duncan M, et al. Imaging features of von Hippel-Lindau disease. *Radiographics*. 2008;28:65–79.
9. Ambrosini V, Campana D, Allegri V, et al.  $^{68}\text{Ga}$ -DOTA-NOC PET/CT detects somatostatin receptors expression in von Hippel-Lindau cerebellar disease. *Clin Nucl Med*. 2011;36:64–65.
10. Oh JR, Kulkarni H, Carreras C, et al. Ga-68 somatostatin receptor PET/CT in von Hippel-Lindau disease. *Nucl Med Mol Imaging*. 2012;46:129–133.
11. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with  $^{68}\text{Ga}$  DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. *Radiographics*. 2015;35:500–516.
12. Papadakis GZ, Bagci U, Sadowski SM, et al. Ectopic ACTH and CRH co-secreting tumor localized by  $^{68}\text{Ga}$ -DOTA-TATE PET/CT. *Clin Nucl Med*. 2015;40:576–578.



**FIGURE 1.** A 46-year-old man with known history of von Hippel-Lindau (VHL) disease and partial resection of right-sided temporal bone mass histologically proven to be endolymphatic sac tumor (ELST) was followed up over a period of 14 years. Surveillance imaging with consecutive MR scans showed stable residual ELST localized within the right temporal bone causing destruction of all right inner ear structures (postcontrast T1-weighted image, white arrows, **A**), markedly enhancing on postcontrast FLAIR images (**B**, yellow arrows). In addition to anatomical imaging, the patient was evaluated with whole-body PET/CT using  $^{68}\text{Ga}$  DOTATATE for the detection of neuroendocrine lesions, showing increased activity ( $\text{SUV}_{\text{max}}$ , 6.29) by the residual ELST (**C**, white arrows). Endolymphatic sac tumors are rare, slow-growing, locally aggressive, low-grade papillary malignancies originating from the epithelium of the endolymphatic duct and sac.<sup>1</sup> Depending on tumor extension, ELSTs present with cochleovestibular dysfunction, sensorineural hearing loss, tinnitus, vertigo, ataxia, disequilibrium, or even facial weakness and glossopharyngeal nerve deficits.<sup>2</sup> Although ELSTs do not give distant hematogenous metastasis, “drop metastasis” to the spinal canal may occur, while death can happen secondary to intracranial vascular compromise.<sup>3,4</sup> Endolymphatic sac tumors can be either sporadic or associated with VHL disease, a familial cancer syndrome characterized by the development of a wide spectrum of benign and malignant tumors.<sup>5</sup> Von Hippel-Lindau–associated ELSTs appear to occur at younger ages, with predilection for women and are more frequently bilateral.<sup>6</sup> Microscopic abnormalities in the epithelium of the endolymphatic sac and duct similar to those of ELSTs are found in VHL patients even though they do not present clinical or radiological manifestations of the tumor.<sup>7</sup> Because multiple VHL manifestations such as hemangioblastomas or pancreatic neuroendocrine tumors are known to overexpress somatostatin receptors (SSTRs), SSTR imaging with radiolabeled SST analogs has been employed in the workup of this disease.<sup>8–10</sup> The conjunction of SST analogs with the chelator DOTA enabled labeling with the PET-emitter  $^{68}\text{Ga}$ , providing compounds with higher affinity to SSTRs compared with those used for conventional SSTR imaging with SPECT. Moreover, the superior resolution provided by hybrid PET/CT makes SSTR imaging using  $^{68}\text{Ga}$  DOTA-conjugated peptides the new standard of reference for the detection and characterization of SSTR-positive lesions.<sup>11,12</sup> The presented case of a VHL-associated ELST showing increased activity on  $^{68}\text{Ga}$  DOTATATE PET/CT suggests cell-surface overexpression of SSTRs and particularly SSTR-2 for which  $^{68}\text{Ga}$  DOTATATE has a predominant affinity. This observation sheds more light to the behavior of this rare tumor and indicates the potential application of PET/CT imaging with  $^{68}\text{Ga}$  DOTATATE in the early detection of ELST, which could enable less morbid operations with higher likelihood for cure and hearing preservation. Furthermore, monitoring of disease progression as well as theranostic application of peptide receptor radionuclide therapy in patients with residual or recurrent ELSTs are potential benefits of SSTR imaging using  $^{68}\text{Ga}$  DOTA-conjugated peptides that need to be further investigated.